Analysis of Health Claims Data for German AD Patients on Conventional Systemic Therapy

Overview

This retrospective cohort study analyzed German health claims data to characterize patients with atopic dermatitis (AD) treated with conventional systemic therapies and to identify indicators of insufficient disease control. The study found a 1-year administrative AD prevalence of 2.4%, highest in young children, with AD-related infections being the most common marker of inadequate control.

Background

Atopic dermatitis is a chronic inflammatory skin disorder with a relapsing course requiring long-term management. In Germany, topical treatments are first-line, but severe or refractory cases may require systemic therapies, including conventional agents like oral glucocorticoids and cyclosporine, or newer biologics and Janus kinase inhibitors. Conventional systemic therapies have limitations, especially for long-term use and pediatric patients. Understanding patterns of systemic therapy use and disease control indicators is essential to optimize management.

Data Highlights

Key Findings

• The overall 1-year administrative prevalence of AD in Germany was estimated at 2.4%, with the highest prevalence in children aged 0–4 years.
• AD-related infections were the most frequent indicator of insufficient disease control among patients treated with conventional systemic therapies.
• Prolonged use of topical treatments and a high number of active flares were also common markers of inadequate disease control.
• Conventional systemic therapies such as oral glucocorticoids and cyclosporine have limitations for long-term use and pediatric patients.
• The study population included patients identified via claims data with documented AD diagnoses and systemic therapy dispensations within defined periods.

Clinical Implications

Clinicians should be aware that conventional systemic therapies may not adequately control AD in all patients, as evidenced by frequent infections and flares. Monitoring for these indicators can guide treatment adjustments. There is a need for improved characterization of systemic therapy use and consideration of newer treatment options, especially for pediatric patients and those with insufficient disease control.

Conclusion

This study highlights the prevalence and challenges of managing AD with conventional systemic therapies in Germany, underscoring the importance of identifying insufficient disease control to optimize treatment strategies.

References

1. German Health Claims Data Study 2023 -- Analysis of Health Claims Data for German Patients with Atopic Dermatitis